Papers
10
Total Citations
154
H-Index
5
About
Asal Rahimi is a radiation oncologist and clinical researcher whose work has fundamentally advanced the use of stereotactic body radiation therapy (SBRT) for early-stage breast cancer, particularly through the development of accelerated partial breast irradiation (APBI) techniques. Her most influential contribution is a pioneering phase 1 dose-escalation trial investigating 5-fraction stereotactic partial breast irradiation (S-PBI), which has garnered 66 citations and helped establish the safety and feasibility of this streamlined treatment approach. Rahimi has further pushed the boundaries of brevity in breast radiotherapy by leading a multicenter phase 1 trial exploring single-fraction S-PBI — a remarkably compressed treatment paradigm that could transform patient convenience. Her research encompasses cosmetic outcome assessment, ultrasound-guided fiducial marker placement, volumetric ultrasound image guidance systems, and, most recently, multi-task deep learning models for multimodal radiotherapy dose prediction, reflecting a forward-looking integration of artificial intelligence into treatment planning. With publications spanning clinical trials, technical innovation, and computational methods, Rahimi's body of work represents a comprehensive effort to make breast cancer radiation therapy more precise, efficient, and patient-centered.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10